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Summary
The genetic determinism of type-1 diabetes in NOD
mice likely involves complementary defects in central
T cell tolerance induction and peripheral immuno-
regulation. To study the contribution of the NOD ge-
netic background to central tolerance, we followed
the behavior of BDC2.5 clonotype thymocytes in fetal
thymic organ cultures (FTOC). The NOD genetic back-
ground encodes a quantitative deficiency in the abil-
ity to delete these self-reactive thymocytes and to di-
vert them to the CD8 lineage. In genetic analyses,
comparing NOD and B6.H2g7 FTOCs, the NOD defect
incorporated the influence of several loci (notably
ones on chr1 and 3). Microarray analyses assessing
FTOCs from the same two strains argued that the
NOD abnormality reflects the combined effects of
turning down the gene expression program that pro-
vokes apoptosis and turning on a new program pro-
moting cell survival. Intersection of the data from the
two approaches points to a small set of attractive can-
didate genes.
Introduction
The induction of T lymphocyte tolerance has two major
facets: peripheral tolerance, wherein regulatory genes
or cells dampen mature T cell activation or effector
function; and central tolerance, in which potentially au-
toreactive T cells are eliminated or silenced at an imma-
ture stage of differentiation in the thymus. The most
definitive mechanism of central tolerance induction is
the clonal deletion of self-reactive thymocytes (reviewed
in Starr et al., 2003). Apoptosis of recalcitrant T cell pre-
cursors occurs when their T cell receptors (TCRs) are
engaged with high affinity by major histocompatibility
complex (MHC) molecule/self-Ag complexes encoun-
tered on thymic stromal cells. The apoptotic pathways
involved remain ill defined, but several critical molecu-
lar players have been identified: Nur77, a transcription
factor, and related family members (Woronicz et al.,*Correspondence: cbdm@joslin.harvard.edu (C.B. and D.M.)
2These authors contributed equally to this work.
3Present address: SISSA-LNM Area Science Park, Padriciano 99,
34012 Trieste, Italy.1994; Calnan et al., 1995); members of the Bcl2 family
of apoptosis control factors, Bim, Bak, and Bax (Rath-
mell et al., 2002; Bouillet et al., 2002); and NF-κB path-
way regulators, in particular IκBNS (Fiorini et al., 2002).
Roles for TNF:TNF receptor family members like Fas-
Fas ligand have also been proposed, but these are
more controversial. Depending on several parameters,
the engagement of TCRs on differentiating thymocytes
by agonist ligands can also promote, rather than delete,
their diversion to alternative cell fates, e.g., selection of
T cells expressing the CD8αα coreceptor and display-
ing innate immune system characteristics (Leishman et
al., 2002; Yamagata et al., 2004) or of CD4+CD25+ T
cells with regulatory properties (Jordan et al., 2001;
Apostolou et al., 2002; Yamashiro et al., 2002).
It has been hypothesized that ineffective central tol-
erance induction in NOD mice, the reference mouse
model of autoimmune diabetes, is an important, though
not the sole, contributor to their propensity to auto-
immunity. Experimental support for this notion has
recently been provided by two approaches. First, ab-
normal clonal deletion of NOD thymocytes after en-
gagement of TCRs by systemic injection of anti-CD3
mAb or of superantigen was reported (Kishimoto and
Sprent, 2001), although this result was later challenged
(Villunger et al., 2003). Second, coupling of a TCR trans-
genic (tg) mouse line with a second tg line expressing
the cognate neo-Ag in the thymus led to drastically re-
duced maturation of CD4+ cells, but this reduction was
much milder in NOD-background mice (Lesage et al.,
2002). The NOD deficiencies in clonal deletion were
specified by non-MHC genes. Interestingly, it has been
proposed that human diabetic patients may have de-
fective clonal deletion of thymocytes reactive to insulin.
This defect is linked to sequence polymorphisms in the
INS promoter that may reduce its expression in the thy-
mus (reviewed in Pugliese and Miceli, 2002), a proposi-
tion consistent with recent results on ins gene knockout
mice (Thebault-Baumont et al., 2003).
The NOD mouse is an invaluable experimental tool,
but diabetogenesis is exceedingly complex even in this
model, with multiple and complex genetic and environ-
mental influences. Thus, a number of investigators
have preferred to focus their efforts on dissecting dis-
ease subphenotypes. One such strategy has been to
employ TCR tg lines that carry the rearranged TCR
genes from a diabetogenic T cell clone, which allow
one to conveniently track the life history of autoreactive
T lymphocytes. The BDC2.5 line derives from a CD4+ T
cell clone, restricted by the NODMHC class II Ag7 mole-
cule and specific for an unknown β cell protein (Katz et
al., 1993; Bergman and Haskins, 1994). This line has
been instrumental in the elucidation of several features
of the immunoregulatory genes or cells that control the
aggressivity of autoreactive T cells in the periphery
(Gonzalez et al., 1997; Kanagawa et al., 2002; Poirot et
al., 2004). Here, we have analyzed the impact of NOD-
background genes on the negative selection of imma-
ture T cells expressing the BDC2.5 clonotype.
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e
fDefective Clonal Deletion in Fetal and Neonatal
BDC2.5/NOD Thymi B
lFor focus and flexibility, we chose to investigate T lym-
phocyte central tolerance induction in NOD mice by p
musing FTOCs. The behavior of thymocytes displaying
the BDC2.5 clonotype afforded a convenient and sensi- t
ative readout. FTOCs derived from congenic BDC2.5
TCR tg mice of the NOD and C57Bl/6.H2g7 (B6g7) genetic (
nbackgrounds were compared, permitting a straightfor-
ward assessment of influences by non-MHC genetic n
aloci. This strain combination was particularly suited to
our needs because a library of Single Nucleotide Poly- t
morphisms (SNPs) distinguishing the NOD and B6 strains
has already been established, and because genetic in- f
mtervals associated with strain-dependent differences in
diabetes susceptibility (Idds) have been defined. t
dThymic lobes dissected from day 15.5 embryos derived
from parallel matings of the BDC2.5/NOD and BDC2.5/ e
aB6g7 lines were cultured as FTOCs for 3–7 days, and
the resulting thymocytes were analyzed for CD4/CD8 N
cprofiles by flow cytometry (Figure 1A, left and center
panels). Lobes from the BDC2.5/NOD cultures looked b
tquite normal in their high proportion of immature
double-positive (DP) thymocytes and predominant se- D
Clection into the CD4-single-positive (CD4-SP) mature T
cell compartment. In contrast, the BDC2.5/B6g7 lobes h
(showed clear hallmarks of clonal deletion: reduced to-
tal thymocyte numbers; a low proportion of DPs, show-
cing reduced expression of CD4; fewer CD4-SPs; and
an increased proportion of CD8-SPs. These differences p
opersisted when CD4/CD8 profiles of cells gated as ex-
pressing the BDC2.5 clonotype were plotted (Figure 1A, e
pright panels).
We then asked whether the deletion-resistant pheno- a
Btype found for BDC2.5/NOD mice was restricted to fetal
thymocytes differentiating in an organ culture system pFigure 1. The NOD Background Prevents Clonal Deletion of BDC2.5 T Cells by Autoantigen
(A) BDC2.5-tg FTOCs were cultured for 3 or 7 days before analysis by flow cytometry. Right panels are gated for the BDC2.5 clonotype. The
bold numbers show the proportion of cells in the populations, and the underlined numbers show the total cell yield per lobe (representative
of three or more experiments).
(B) Thymic lobes from newborn mice of the same transgenic lines were analyzed as described in (A).
(C) No difference in clonal deletion in nontransgenic FTOCs (left) or neonates (right).r whether the same phenotype could be demonstrated
x vivo. In a previous study (Gonzalez et al., 1997), we
ound no differences between adult BDC2.5/B6g7 and
DC2.5/NOD thymi, with no overt signs of negative se-
ection on either background. However, it remained
ossible that cues for or mechanisms of clonal deletion
ight be developmentally regulated, so we analyzed
he phenotype of BDC2.5/NOD and BDC2.5/B6g7 mice
t late (d18–19) embryonic (not shown) and postnatal
Figure 1B) stages. Thymi from neonates exhibited phe-
otypes that paralleled those observed in FTOCs: a
ormal aspect in BDC2.5/NOD thymi, contrasting with
clear imprint of negative selection in BDC2.5/B6g7
hymi, with as low as 28% DP thymocytes.
Thus, the NOD genetic background appeared to con-
er resistance to clonal deletion in differentiating thy-
ocytes that express the BDC2.5 specificity. Non-tg lit-
ermates were analyzed in order to confirm that the
ifferent profiles resulted from specific deletion of cells
xpressing the self-reactive clonotype, rather than from
differential susceptibility of embryonic thymi of the
OD versus B6.H2g7 genetic background to the culture
onditions. FTOCs and neonatal thymic lobes from
oth genetic backgrounds showed a normal represen-
ation of thymocyte compartments, in particular healthy
P compartments (Figure 1C). A difference in the CD4/
D8 ratios was observed, consistent with the generally
igher proportion of CD4+ cells in the NOD mouse
Zhang et al., 1994).
Clonal deletion of thymocytes expressing the BDC2.5
lonotype observed in FTOCs likely reflects ectopic ex-
ression in thymic epithelial cells (Kyewski et al., 2002)
f low amounts of the BDC2.5 autoAg; this molecule’s
xpression appears otherwise to be restricted to the
ancreas (Bergman and Haskins, 1994). It is conceiv-
ble that BDC2.5/B6g7 FTOCs express more of the
DC2.5 autoAg than do BDC2.5/NOD cultures, thereby
roviding an explanation of the above results. To evalu-
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control of the level of autoAg, we performed FTOC ex-
periments in the presence of graded amounts of a mi-
motope peptide that activates mature BDC2.5 T cells
(BDCmi; [Judkowski et al., 2001]). In keeping with the
results obtained on untreated cultures, BDC2.5/B6g7
lobes exhibited a much greater sensitivity to this ago-
nist than did the BDC2.5/NOD lobes cultured in parallel
(Figures 2A–2C). In BDC2.5/B6g7 thymi, DP cells were
essentially wiped out by the addition of 1 ng/ml pep-
tide, leaving behind only a few double-negative (DN)
precursors and CD8-SP cells; the same dose had little
effect on BDC2.5/NOD lobes, which required up to 100
ng/ml peptide for a comparable degree of depletion.
Thus, the different outcomes of the BDC2.5/NOD and
BDC2.5/B6g7 FTOCs appeared to reflect a 50- to 100-
fold difference in sensitivity to clonal deletion, not in
the expression level of autoAg.
The inefficient deletion of self-reactive thymocytes
on the NOD genetic background could stem from eitherFigure 2. Decreased Sensitivity of NOD Background Thymocytes to Peptide-Induced Deletion
(A) BDC2.5-tg FTOCs were cultured for 7 days with graded doses of BDCmi and were analyzed by flow cytometry (representative of more
than five experiments).
(B) Absolute cell counts per lobe from the experiment shown in (A).
(C) Differences among groups of BDC2.5/B6g7 (black symbols) or BDC2.5/NOD (white symbols) cultures; each point represents an FTOC lobe.
(D) Reconstitute FTOCs were assembled by mixing sorted T precursors and deoxyguanosine-treated stromal cells and were evaluated by
flow cytometry.
(E) Induction of proapoptotic molecules, as measured by RT-PCR in peptide-stimulated sorted DP FTOC cells.altered autoAg presentation by thymic stromal cells or
from an autonomous defect in the response elicited in
immature T cells. To distinguish between these two possi-
bilities, we constructed chimeric fetal thymus lobes
(Figure 2D): stromal cells from deoxyguanosine-treated
E15 lobes were reconstituted with sorted DN T cell pre-
cursors (depleted of CD11c+, CD11b+, MHC class II+
antigen presenting cells [APCs]) in all four possible
combinations of genetic background. Independent of
whether the stromal cells were of NOD or B6g7 origin,
seeding with BDC2.5/B6g7 T cell precursors recapitu-
lated the deletion-sensitive phenotype (low % DP cells),
while introducing BDC2.5/NOD T precursors yielded
cultures that were significantly more resistant to dele-
tion. Thus, the impaired ability to delete BDC2.5 T cells
in thymi of NOD mice resides with the thymocytes
themselves, consistent with observations on the TCR/
neo-self-Ag double-tg system mentioned above (Le-
sage et al., 2002).
One might predict that this greater propensity to die
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388would be reflected in a differential balance of pro- and n
Oantiapoptotic mediators. We tested the induction of
two such elements, known to be essential in thymic a
aclonal deletion, Nur77 and Bim (Calnan et al., 1995;
Bouillet et al., 2002). As illustrated in Figure 2E, both m
were induced at higher levels in BDC2.5/B6g7 than in f
BDC2.5/NOD DP cells by peptide addition. t
d
Compromised Diversion to the CD8 Lineage p
in NOD-Background FTOCs p
While strong agonist ligand engagement of TCRs in the b
thymus has classically been linked to clonal deletion, (
recent studies have demonstrated that it can also elicit R
differentiation along alternative pathways, such as the i
CD8αα lineage (Leishman et al., 2002; Yamagata et al., t
2004). Having established that the efficiency of thymo- w
cyte clonal deletion differs between BDC2.5/NOD and v
BDC2.5/B6g7 thymi, we exploited our FTOC system to s
determine whether thymi of the two strains also diverge r
in their ability to redirect self-reactive thymocytes into S
the CD8αα lineage. BDC2.5/B6g7 FTOCs contained
significant numbers of CD8αα thymocytes, and the ra- o
tio of CD8αα to CD8αβ cells increased with mimotope F
peptide dose, ultimately resulting in nearly complete n
“conversion” to CD8αα cells at high peptide concentra- e
tions (Figure 3A, top panels). In contrast, BDC2.5/NOD s
FTOCs yielded CD8αα thymocytes only in the presence d
of 30- to 100-fold higher BDCmi concentrations (Figure H
3A, bottom panels), a shift similar to that found for the m
deletion curves of DP and CD4-SP cells (Figures 2A and d
2B). Furthermore, in BDC2.5/NOD FTOCs, as peptide B
concentration was increased, depletion of the general t
population of CD8-SP cells preceded the increase in t
the CD8αα component. This trend, combined with the s
consistently lower numbers of CD8-SPs observed in B
BDC2.5/NOD cultures, resulted in far lower yields of 4
CD8αα cells at all but the highest concentrations (Fig- u
ure 3B). Thus, a failure to “disarm” self-reactive T cells t
by diverting them to an alternative lineage accompa- G
nies the deficiency in clonal deletion characteristic of s
NOD thymocytes. r
F
NBroad Differences in Gene Expression Profiles
What changes in gene expression underlie the dif- i
lferential sensitivity to clonal deletion of the BDC2.5 clo-Figure 3. Defective Commitment to the CD8αα+ Lineage in Agonist-Stimulated NOD Thymocytes
(A) BDC2.5-tg FTOCs were cultured for 7 days with graded amounts of BDCmi and were analyzed by flow cytometry (gated on total thymo-
cytes).
(B) Absolute numbers of CD8αα thymocytes obtained from BDC2.5-tg FTOCs, ±SD.otype on the NOD versus B6g7 genetic backgrounds?
ur initial analyses showed a stronger induction of pro-
poptotic molecules on the B6g7 background; but, for
broad perspective on this question, we performed
icroarray analysis on thymocytes of FTOCs derived
rom BDC2.5/NOD and BDC2.5/B6g7 embryos and cul-
ured in the presence of BDCmi peptide subsequent to
ay 3. The lobes were dissociated 0, 2, or 16 hr after
eptide addition in order to span the initiation of apo-
tosis; thymocytes remained fully viable at those times,
eginning to disappear only 24 hr after peptide addition
data not shown). DP thymocytes were isolated, and
NA was prepared, amplified, and labeled for hybrid-
zation to Mu74Av2 Affymetrix gene chips. Data from
hree completely independent replicates per condition
ere processed and normalized as described pre-
iously (Yamagata et al., 2004), with estimates of the
ignificance of the variations observed deduced from
andomized data sets (full results are shown in Table
1; see the Supplemental Data available online).
Figure 4A portrays the changes in gene expression
bserved 16 hr after addition of the BDCmi peptide.
or both the BDC2.5/NOD and BDC2.5/B6g7 FTOCs, a
umber of genes depart from the midline of equivalent
xpression. The blue dots highlight genes demon-
trated in studies published by other groups to be in-
uced during negative selection (Schmitz et al., 2003;
uang et al., 2004; DeRyckere et al., 2003). Indeed,
ost of these previously implicated genes were in-
uced at 16 hr in our system as well, particularly in the
DC2.5/B6g7 cultures, thus instilling confidence that
he variations we observed are relevant. For example,
ranscripts from the Nur77 gene were found to be
trongly induced, more so in BDC2.5/B6g7 than in
DC2.5/NOD FTOCs. A time course analysis (Figure
B) demonstrates that these genes were only slightly
pregulated at 2 hr, but significantly at 16 hr. These
rends extended to unexpected genes as well: the
add45b gene transcript, for instance, displayed the
ame pattern. In all, 37 and 86 genes were induced or
epressed (respectively) more than 2-fold in BDC/B6g7
TOCs, versus only 14 and 0 (respectively) for BDC2.5/
OD cultures. Thus, although several genes typically
nduced during negative selection were also upregu-
ated on both the NOD and B6g7 backgrounds, these
Genetics of Central Tolerance
389Figure 4. Broad Induction of the Apoptosis-
Related Genes in BDC2.5/B6g7 versus
BDC2.5/NOD
(A) BDC2.5-tg FTOCs were cultured for 3
days in the absence of peptide followed by
peptide challenge. mRNA was harvested
from sorted DP thymocytes and hybridized
to Mu74Av2 chips. Blue genes exhibited dif-
ferential expression in previous studies of
negative selection. The numbers of genes
that are induced or repressed more than
2-fold are shown.
(B) The kinetics of genes induced more than
2-fold for BDC2.5/B6g7 or BDC2.5/NOD.increases were distinctly less marked on the former,
consistent with the resistance of NOD thymi to clonal
deletion.
We then analyzed more profoundly the differences
observed between the BDC2.5/NOD and BDC2.5/B6g7
expression profiles. In theory, one might have expected
two categories of differentially expressed genes, both
of which could have a causative relationship with the
efficacy of clonal deletion. The first category corres-
ponds to genes whose expression differences are con-
stitutive, i.e., exist prior to and independent of the
negative selection trigger. Such genes represent “bed-
rock” variation between the NOD and B6g7 strains, and
a substantial number showed this pattern (Figure S1):
with a cutoff of 2.0-fold, 25 and 17 genes were consis-
tently expressed at a higher level in B6g7 and NOD thy-
mocytes, respectively, whether peptide was present or
not, and also in cells from non-tg lobes. Most of these
differences had also been seen in microarray data sets
obtained from lymph node CD4+ T cells of BDC2.5/NOD
or BDC2.5/B6g7 mice (data from Poirot et al., 2004).
The second category of differentially expressed
genes consists of those that show a difference only
subsequent to induction of negative selection by ago-
nist peptide. This pattern of expression might indicate
that these genes’ responsiveness is intrinsically dif-
ferent or might reflect that they belong to a pathway
that is differentially triggered in the two genetic back-
grounds. In other words, the muted BDC2.5/NOD pro-
file could simply reflect a duller induction of the same
panel of genes or represent the induction of a different
gene set. To facilitate visualization of this category, we
plotted all of the genes induced after 16 hr of incuba-
tion with mimotope peptide in BDC2.5/B6g7 and
BDC2.5/NOD lobes in Figures 5A and 5B, respectively.
Among those genes upregulated in the BDC2.5/B6g7
FTOCs, only a minority were also induced in the
BDC2.5/NOD cultures (16 of 252 genes at a fold-
change cutoff of 1.5). Conversely, of the 127 genes in-
duced in BDC2.5/NOD cultures, only 15 were upregu-
lated in BDC/B6g7 FTOCs, while most were uninduced
or even slightly repressed. A notable example is the
signal for the antiapoptotic gene bcl2, which showed a2.25-fold increase on the NOD background, but not on
the B6g7. This sense of distinct sets of induced genes
is reinforced by the plot of Figure 5C, which shows, for
all genes upregulated on either genetic background,
the ratio of inducibility on the B6g7 versus NOD back-
grounds (ratio of the 16 hr/0 hr fold-change values).
While a main swath of genes has a B6g7/NOD inducibil-
ity ratio > 1, another subset is clearly distinguished be-
low the line of equivalence. The nature of the genes
specifically induced on the NOD background is intrigu-
ing: many of them are interferon inducible or are related
to transcriptional/translational control (Figure 5C, right)
(further discussed below). Thus, the resistance to ago-
nist-induced apoptosis on the NOD background is
marked both by a dampening of the normal response
and by the induction of a qualitatively different gene
expression program.
Positioning the Causal Genetic Variation
Which, if any, of these gene expression differences
might be causal, actually determining protection from
clonal deletion on the NOD background? We performed
a genetic mapping study to address this question, first
testing for phenotypic dominance by flow cytometric
analysis of thymocytes derived from F1 (BDC2.5/B6g7 ×
NOD) FTOCs. F1 thymocytes were as resistant to dele-
tion as NOD thymocytes (if not more so), in either the
presence or absence of BDCmi peptide (Figure 6A).
Thus, the resistance phenotype characteristic of the
NOD mouse is largely dominant.
To map the underlying quantitative trait loci (QTL),
and in a variation of the classic F2 intercross mapping
strategy, we set up FTOCs from F2 embryos. A total of
306 BDC2.5+ (B6g7 × NOD) F2 cultures were tested in
two different cohorts: the first consisted of 123 cultures
incubated in the absence of added peptide; the other
183 were incubated in the presence of the BDCmi pep-
tide at 10 ng/ml, a dose chosen because it provokes
significant deletion of BDC2.5/B6g7 thymocytes while
only marginally affecting BDC2.5/NOD cells. The F2s
exhibited a range of phenotypes, skewed toward the
NOD phenotype (Figure 6B), consistent with the appar-
Immunity
390Figure 5. Distinct Pattern of Gene Induction in BDC2.5/B6g7 and BDC2.5/NOD
(A) Fold induction and ranking for the genes induced more than 1.5-fold in BDC2.5/B6g7 at 16 hr versus 0 hr (red), and their parallel induction
for BDC2.5/NOD (blue). Listed are the top 33 genes induced in BDC2.5/B6g7. Induction and repression of more than 1.5-fold are color coded
in orange and blue, respectively.
(B) The same plot as in (A) for the genes induced more than 1.5-fold in BDC2.5/NOD (blue) and their fold induction in BDC2.5/B6g7 (red).
(C) The ratio of inducibility (B16/B0 divided by N16/N0) versus inducibility rank. Listed are the top 21 genes ordered by inducibility in NOD
versus B6g7.
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(A) BDC2.5-tg FTOCs were cultured for 7 days without added peptide (squares) or with 10 ng/ml BDCmi (circles) and were analyzed by flow
cytometry (compiled from three or more experiments).
(B) Phenotypic distributions for BDC2.5/F2 FTOCs incubated without added peptide (open circles) or with 10 ng/ml BDCmi (filled circles).
(C and D) LOD plots for the (C) no-peptide and (D) plus-peptide FTOC BDC2.5/F2 cohorts.ent dominance of NOD alleles in the F1, and with the
existence of several controlling QTLs.
A genome-wide scan was then performed on geno-
mic DNA from the 306 F2 embryos, genotyped by fluo-
rogenic PCR for a set of 147 SNP markers distinguish-
ing the NOD and B6 genomes. The markers covered all
19 autosomes, in particular known diabetes-linked Idd
loci, with an average spacing of approximately 16 Mb.
Tabulations of the full marker set and of the genotyping
results are available as Supplemental Data (Tables S2
and S3). The %DP and %DN values were chosen as
the main quantitative traits in this analysis because: a)
these metrics most clearly and consistently reflected
the differences between NOD and B6g7 FTOCs (Figures
2 and 6A); b) clonal deletion in this instance operates
on the DP population, while the DN precursors remain
relatively fixed in number; thus, their proportion pro-
vides a reasonably robust metric of deletion. We did
not track the proportion of CD4-SP cells, a priori a logi-
cal choice for an MHC class II-restricted T cell clono-
type, because of the additional variability imparted by
agonist-induced selection toward the CD8αα lineage.
The total cell number per lobe also proved unreliable,
as yields in individual FTOCs fluctuate markedly, even
when comparing genetically homogeneous embryos.
Simple trait/marker association and interval mapping
(S-plus, Mapmaker/QTL, R/qtl) gave rise to very similar
results (Figure 6C). For the cultures without peptide ad-
dition, which relied on the limited amount of endoge-
nous BDC2.5 Ag to provoke clonal deletion, a major
peak was found on Chr1, with LOD scores of 4.2 and
5.9 for %DP and %DN QTs, respectively, and account-
ing for 15.2% of the variance. Permutation tests (R/qtl,
10,000 permutations) established that these peaks
were well within the range of significant linkage, with
an experiment-wise empirical p value of 0.05 at LODof 3.49. The NOD allele was fully dominant and was
associated with high DP and low DN values, consistent
with the NOD phenotype being largely dominant in the
F1 (Figure 6A). Lesser linkage peaks, e.g., on Chr2, 4,
13, and 18, remained in the “suggestive” range. Thus,
resistance to negative selection at low peptide doses
potentially maps to multiple loci in the NOD genome,
but with a dominant region on Chr1.
A different profile was found with the peptide-supple-
mented F2 cohort, with a major peak on Chr3 (LOD =
14.2) (Figure 6D), and secondary peaks on Chr1, 7, 11,
and 19. Chr3 was calculated to contribute 31.2% of the
variance under these conditions. For all of these loci,
the NOD allele was again found to be associated with
high %DP and low %DN. The divergent profile com-
pared with that of the F2 cohort with no peptide addi-
tion indicates that different pathways might be in-
volved: at low levels of deleting signal, a polymorphism
(or polymorphisms) on Chr1 has (have) the principal in-
fluence; but, stronger deleting signals, which likely
overcome the resistance imparted by Chr1 loci, un-
mask the influence of Chr3. Interestingly, Sprent and
colleagues have reported a similar dichotomy in molec-
ular requirements for clonal deletion of mature thymo-
cytes, differing according to ligand avidity (Kishimoto
et al., 1998).
As discussed above, the %DP and %DN values were
considered the most useful metrics of clonal deletion.
However, we also observed strong evidence for linkage
by using %CD8-SP as a QT, independent of clonal dele-
tion. For both the no-peptide and plus-peptide cohorts,
a broad peak was observed in the central region of
Chr7 (LOD scores of 4.5 and 4.8, respectively; com-
bined LOD score of 9.69; Figure S2). High %CD8-SP
values were associated with the B6 allele in a largely
dominant fashion. Its high values did not correlate with
Immunity
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lcommitment to the CD4 versus CD8 lineages (Figure 3
and discussed above), or to thymocyte survival and N
lpersistence.
These results were largely confirmed by using a non- t
nparametric interval mapping algorithm in R/qtl and
composite interval mapping in Win/QTL Cartographer.
Searching for epistatic interactions with two-dimen- D
sional scanning in R/qtl yielded suggestive epistatic ef-
fects between Chr1 and Chr4, but permutation tests T
revealed that the evidence for interaction did not meet T
statistically stringent criteria. t
t
bMerging Gene Expression Profiling
and Genetic Mapping a
BThe experimental logic behind our parallel gene expres-
sion profiling and genetic mapping analyses was that o
ithe data sets would crosscomplement, focusing atten-
tion on differentially expressed genes or gene families s
rmapping under the genetic linkage peaks. For in-
creased resolution, additional SNPs mapping to the p
Chr1 and Chr3 regions were typed, and confirmatory
RT-PCRs were performed for those candidate genes g
tshowing suggestive differences in the microarray data.
On Chr1, the main genetic interval mapped telomeric t
Cof the Idd5 subregions (ctla4, nramp) that have been
shown to influence diverse aspects of peripheral toler- l
eance induction (Sharpe and Freeman, 2002) (Figure 7A).
Several genes within this interval did, however, exhibit I
asuggestive microarray profiles (Figure 7B). The first two
of these are particularly striking because of their known i
crelevance to apoptosis: PD1 (pdcd1, 94 Mb), previously
implicated in the control of immune tolerance (Nishi- c
imura et al., 1999), was induced 17-fold by addition of
the BDCmi peptide in BDC2.5/B6g7 FTOCs, but only
s4.8-fold in BDC2.5/NOD cultures. (Confirmatory PCR
data for this and other attractive candidates are pre- t
esented in Figure 7C.) Conversely, the bcl2b isoform was
upregulated in BDC2.5/NOD relative to BDC2.5/B6g7 e
Ncultures. Another gene that could potentially act as a
modifier of negative selection is the protein phospha- n
itase ptprv, which might modulate TCR signals and was
overexpressed in FTOCs of NOD genetic background, o
rprior to and independent of TCR engagement by ago-
nist. In addition, two uncharacterized ESTs were over- t
rexpressed in BDC/B6g7.
The associated interval on Chr3 includes or is flanked f
iby several Idd regions (Figure 7A). Idd3 maps some-
what outside this interval, as do Idd10 and Idd18 (Lyons d
met al., 2000; Lyons et al., 2001), and their likeliest candi-
dates have no obvious connection to the clonal dele- d
Ation phenotype. On the other hand, the Idd17 region
(80–88 Mb) is included in our Chr3 interval associated m
awith ineffective clonal deletion (Lyons et al., 2001). As
with Idd3/10/18, the Idd17 interval contains no glaring l
2candidates expected to influence negative selection.
We do note the differential induction of Narg1 (“NMDA s
areceptor-regulated gene 1”) (Figure 7B) and Ash1l, but
it is not clear how these molecules would affect clonal T
adeletion. The CD1d1 gene makes a more interesting
candidate because of its involvement in activation- c
binduced death of peripheral T cells (Dao et al., 2001),
as does the Sh2d2a gene (aka TSAd, or “lck adaptor pritical for cell death”), which lies just outside the pub-
ished borders of Idd17. It is far less induced in BDC2.5/
OD than in BDC2.5/B6g7 FTOCs, and one can specu-
ate that this differential upregulation is at the root of
he different transcription programs engaged by ago-
ist on the two genetic backgrounds.
iscussion
he data presented herein confirm and extend, for a
CR/Ag pair involved in spontaneous autoimmunity in
he NOD mouse, previous reports demonstrating resis-
ance of NOD thymocytes to clonal deletion triggered
y an anti-CD3 mAb (Kishimoto and Sprent, 2001) or by
transgene-encoded neo-self-Ag (Lesage et al., 2002).
ecause of an intrinsic variation in the interpretation
r transmission of signals received through the TCR,
mmature thymocytes of the NOD genetic background
eemed to be far more resistant to death provoked by
ecognition of self-MHC/Ag complexes. Titration ex-
eriments revealed a hundred-fold differential.
In addition to a resistance to clonal deletion, the NOD
enome imparts a reduced ability to divert self-reactive
hymocytes into an alternative pathway of differentia-
ion that results in T cells of the CD8αα phenotype. As
D8αα thymocytes are precursors of intraepithelial
ymphocytes (IELs) (Leishman et al., 2002; and refer-
nces therein), this aberrancy may lead to a reduced
EL compartment in NOD mice. Thus, the genetic vari-
nt(s) underlying the NOD defect in T cell tolerance may
mpinge at an early point of the signal transduction cas-
ade initiated by engagement of the TCR on thymo-
ytes, upstream of the divergence between apoptosis
nduction and CD8αα differentiation.
The defects in clonal deletion and diversion likely re-
ult in an enrichment for autoreactive specificities in
he nascent T cell repertoire of NOD mice, providing an
xplanation for their propensity to autoimmune dis-
ase. However, this is not the only level at which the
OD genome controls the development of autoimmu-
ity or of autoimmune disease. Autoimmunity is also
nfluenced by peripheral tolerance, governing the ability
f the autoreactive repertoire to be activated and/or
egulated. Different genes or clusters of genes might,
o at least some degree, be involved in central and pe-
ipheral tolerance phenomena, e.g., the CTLA-4/ICOS
amily of costimulatory molecules does not seem to be
nvolved in the events described here, mapping to a
istinct region of Chr1. Overt development of autoim-
une disease—in the present context, the insulitis to
iabetes conversion—is regulated by still other factors.
nd herein lies the explanation for why BDC2.5/B6g7
ice actually succumb to type-1 diabetes more rapidly
nd penetrantly than do BDC2.5/NOD animals (Gonza-
ez et al., 1997). As recently reported (Poirot et al.,
004), NK cells are powerful regulators of the aggres-
ivity of the insulitic lesion, and the B6 background is
ssociated with a more potent NK cell compartment.
he genetic control of autoimmune disease plays a bal-
ncing act, and a propensity to poor central tolerance
an coexist with stronger peripheral tolerance, possi-
ly, but not necessarily, because of the same polymor-
hisms.
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(A) Linkage maps for Chr1 (no-peptide cohort) and Chr3 (plus-peptide cohort). Idd regions identified in previous studies are indicated by
horizontal bars.
(B) Microarray expression data for all genes represented on the chip for Chr1 and Chr3, presented as the log2 of the expression ratio for
BDC2.5/B6g7 versus BDC2.5/NOD after 16 hr of peptide challenge. Highlighted are genes located within the causal genetic intervals that
exhibit bedrock expression differences (blue) or differential induction over time (red). Several genes/ESTs that showed suggestive expression
profiles at 16 hr were excluded as candidates for the reasons indicated (Supplemental Data).
(C) Expression data from quantitative RT-PCR (PD1, Ptprv, Sh2d2a) or microarray (Bcl2b) analyses of mRNA from sorted FTOC DPs (gray bar,
BDC2.5/NOD; black bar, BDC2.5/B6g7).Even though it is implicit from the experimental set-
up, which entails the same MHC in both BDC2.5/NOD
and BDC2.5/B6g7 mice, one should stress that the re-
sistance to clonal deletion we have explored does not
involve the MHC, but other genetic regions. It has been
proposed that the NOD MHC class II isoform Ag7 (and
its DQ8 homolog in humans) may predispose to auto-
immunity through altering the kinetics/specificity of
antigen presentation (reviewed in Nepom and Kwok,
1998). The phenomenon described here operates in ad-
dition to any impact the MHC may have on differential
selection of autoreactive T cells. Interestingly, the dele-
tion-resistant phenotype imparted by the NOD allele
appears dominant, which contrasts with the recessive
nature of diabetes susceptibility overall in NOD out-
crosses.
Multiple genetic intervals were implicated in the sub-
phenotype we explored, even though a priori it seemed
to be a relatively simple one. Different intervals domi-
nated when endogenous antigen was presented at low
doses versus when the TCR was more decisively en-
gaged by higher doses of peptide that was exoge-
nously added. Specifically, the Chr1 interval became
less important and the Chr3 interval took precedence.
Such a dichotomy is reminiscent of a previous reportthat different signaling pathways may come into play
during thymocyte deletion at high and low ligand con-
centrations (Kishimoto et al., 1998). The constellation
of loci capable of modulating negative selection that
has accumulated in the NOD genome probably reflects
the selection pressure applied during the derivation of
this inbred strain (Makino et al., 1980). It also suggests
that the Mus species, as a whole, may benefit from
maintaining a pool of genetic variation able to dampen
repertoire attrition through negative selection, perhaps
to avoid repertoire “holes” for specificities needed to
effectively confront microbial challenges.
Genomics
The broad perspective offered by the microarray and
PCR analyses revealed two main molecular aspects to
the NOD strain’s resistance to clonal deletion. First,
there was a reduced induction of key molecules of the
apoptotic pathway, including Nur77 and Bim. This
dampening extended to many other genes as well:
those transcripts most strongly induced by clonal dele-
tion triggers on the B6g7 background did show a de-
tectable, but weak, increase on the BDC2.5/NOD back-
ground, but the remainder of the response profile was
essentially null. Preliminary results suggest that the re-
Immunity
394duction in RNA transcript levels is transcriptional and, R
tat least for the Nur77 locus, stems from a difference
ein chromatin accessibility (M. Fassett, D.M., and C.B.,
tunpublished data). A second key facet to the differential
sresponse was that BDC2.5/NOD cells engaged a dis-
ctinct program of transcription. Many of the genes in-
2duced in BDC2.5/NOD thymocytes were unaffected, or
teven repressed, in thymocytes of the B6 background.
eA preferential induction of the antiapoptotic molecule
pFLIP after anti-CD3 triggering has been reported for
bNOD mice vis a vis B6 (Kishimoto and Sprent, 2001),
bbut the present microarray data did not reproduce this
bdifference. Rather, our results indicated that FLIP was
oone element of a much broader response induced in
pBDC2.5/NOD thymocytes, including Bcl2 and a number
Tof other survival factors.
eThe list of genes preferentially induced in BDC2.5/
tNOD FTOCs is highly suggestive and includes genes
Cinvolved at three levels of genetic control: transcription,
rtranslation, and interferon (IFN)-mediated regulation.
lThe transcription factor Ets-1 promotes T cell survival
p(reviewed in Sementchenko and Watson, 2000). The
(RNA splicing factor Rbmx and histone-acetyltransfer-
sase Pcaf may regulate broader gene transcription pro-
Bgrams. Translational arrest is associated with the in-
mduction of apoptosis, in part through inactivation of
ptranslation preinitiation complexes (Clemens et al.,
t2000). Thus, upregulation of Eif3s10 and Eif2s3y is likely
mto confer resistance to apoptosis in NOD thymocytes.
pIFN signaling is connected to apoptosis, growth arrest,
Fand cell cycle progression (Stark et al., 1998). A surpris-
ringly high number of inteferon-controlled genes scored
iin our analysis (7 out of 21). Isg15 is the IFN-inducible
tmember of the ubiquitin-like family of proteins, which
imodifies IFN signaling by conjugating to multiple target
pproteins. Ubp43, another IFN-induced protein with de-
Lubiquitinase activity, specifically cleaves Isg15 from its
Ntarget proteins. The presence of two biochemically
wconnected genes in this rather short list points to pre-
ncise and coordinated regulation of the IFN signaling
tpathway during clonal deletion. Even more striking is
Tthe group of interferon-inducible GTPase (IIGP) family
jmembers (Irg47, Gtpi, Igtp, and Gbp3) reported to exert
g
antiapoptotic effects through Akt activation and sup-
c
pression of Caspase-9 and Caspase-3 (Zhang et al.,
c
2003). In short, then, apoptosis is inhibited in thymo- w
cytes of the NOD background through active induction g
of a broad array of antiapoptotic functions. o
a
Genetics d
Intersection of the gene expression profiling and whole- w
genome screening data highlighted some very attrac- r
tive candidate genes potentially responsible for the NOD S
strain’s resistance to clonal deletion of self-reactive thy- n
mocytes. 2
bcl2
The classic antiapoptotic gene, bcl2, maps to the impli- d
cated interval on Chr1, and it showed up as upregu- m
lated in NOD FTOCs in our genomic analysis. Over- or i
underexpression of Bcl2 per se has not thus far been d
tied to thymocyte clonal deletion (Sentman et al., 1991), r
but it is noteworthy that the B6 versus NOD difference m
cdetected in our microarray analysis, and confirmed byT-PCR, concerned the contribution of splice forms of
he transcript rather than overall transcript levels. The
xistence of Bcl2 splice variants was reported some
ime ago, but their functional implications remain ob-
cure. There have been recent reports of Bcl2 physi-
ally interacting with both Nur77 and Bim (Lin et al.,
004; Zhu et al., 2004), so it is tempting to speculate
hat an altered ratio of Bcl2 splice forms might influ-
nce the proapoptotic activities of Bim/Nur77 through
referential binding of one form or the other. It would
e particularly interesting if it were to turn out that the
cl2 gene follows the precedent of the ctla4 gene in
eing controlled by preferential splicing in NOD versus
ther mouse strains.
dcd1
he PD-1 gene (pdcd1), whose transcription was mark-
dly underactivated in BDC2.5/NOD FTOCs, maps close
o the bcl2 locus. PD-1 is a member of the CTLA-4/
D28/ICOS family of costimulatory molecules, and its
elevance to apoptosis and autoimmunity was estab-
ished by the phenotype of PD-1-deficient mice, which
resent with uncontrolled autoreactive lymphocytes
Nishimura et al., 1999) although an impact on negative
election was not demonstrated (Blank et al., 2003).
lockade of PD1 elicited rapid-onset diabetes in NOD
ice, consistent with a role in peripheral tolerance
athways (Ansari et al., 2003). Our data suggest that
he NOD allele might act as a poorly inducible hypo-
orph.
tprv and Tsad
inally, the ptprv and Tsad genes (on Chr1 and Chr3,
espectively) are interesting candidates, both higher up
n the signal transduction pathway. Ptprv, a receptor-
ype tyrosine phosphatase not thoroughly investigated
n the immunological context, was consistently overex-
ressed in BDC2.5/NOD FTOCs. TSAd (aka Sh2d2a,
ad, RIBP), induced in BDC2.5/B6g7 but not BDC2.5/
OD cultures, is an SH2 adaptor protein that interacts
ith Lck and Itk at the very apex of TCR-mediated sig-
aling and may have a role as an activating transcrip-
ion factor. It was previously associated with defective
cell death and autoimmunity (Drappa et al., 2003; Ra-
agopal et al., 1999). For both the ptprv and Tsad genes,
enetic variation in the basal expression or inducibility
ould affect the intensity or quality of the signal re-
eived through the TCR, in a manner that conditions
hether this signal ends up triggering a B6-like pro-
ram (culminating in the activation of Nur77 and Bim)
r a NOD-like program (arriving predominantly at Ets-1
nd other survival factors). It may not be just a coinci-
ence that two genes recently found to be associated
ith type-1 diabetes in humans, those encoding the ty-
osine phosphatase PTPN22 and the IκBα modifier
UMO-4, also influence proximal signaling events ema-
ating from the TCR (Bottini et al., 2004; Bohren et al.,
004).
As in the multiorgan autoimmune diseases of aire-
eficient mice and AIRE-defective patients, autoim-
une diabetes in NOD mice is (at least partially) rooted
n a fundamental defect in T cell central tolerance in-
uction, more specifically in clonal deletion of self-
eactive thymocytes. Unlike the disease of patients or
ice with a mutation in AIRE, wherein autoreactive T
ells emerge from the thymus because of a defect in
Genetics of Central Tolerance
395stromal cell function, the central tolerance deficit we
have uncovered in NOD mice is intrinsic to the T cell
lineage. Thus, defective T cell central tolerance induc-
tion in type-1 diabetes, in NOD mice or in human pa-
tients, can be caused by genetic variation at (at least)
three levels: because presentation of the autoantigen
in the thymus is limiting; because the intracellular chan-
neling of signals emanating from the TCR activates sur-
vival rather than apoptosis of thymocytes (through vari-
ation in ptprv or PTPN22, for example); or because of
variability in the level of basal expression or inducibility
of molecules that control the final pro-/antiapoptotic
balance. That the genetic mapping of autoimmune dia-
betes has been so challenging may not be a surprise
in hindsight.
Supplemental Data
Supplemental Data including technical details (Experimental Pro-
cedures) are available at http://www.immunity.com/cgi/content/full/
22/3/385/DC1/.
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